About the Product

Description


Cufsniff 30 Tablet containing Ambroxol is used for the management of cough associated with mucus production and respiratory congestion. It helps improve breathing comfort by clearing mucus from the airways.

Ambroxol works as a mucolytic agent that thins and loosens mucus, making it easier to expel from the respiratory tract and supporting better lung function.

The tablet is widely prescribed in respiratory care practice for productive cough and chest congestion, leading to consistent prescription demand.

With increasing prevalence of seasonal respiratory infections and cough-related conditions, this product offers strong business potential for retailers and distributors. Its effective mucus-clearing action, broad clinical relevance, and steady market demand make it a reliable product for growth in the respiratory segment.

Some patients may experience nausea, dry mouth, stomach discomfort, mild vomiting, or allergic skin reactions. Rarely, dizziness or hypersensitivity reactions may occur.

Cufsniff 30 Tablet is indicated for productive cough, bronchitis, asthma with mucus, chronic obstructive pulmonary disease (COPD), and chest congestion. It helps clear mucus, improve breathing, and reduce cough severity.

This medicine should be used under medical supervision. Drink adequate fluids during therapy to improve effectiveness. Use cautiously in patients with gastric ulcers or severe kidney/liver disorders.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Cufsniff 30 Tablet in the PCD pharma franchise market?

Cufsniff 30 Tablet, containing Ambroxol 30mg, has strong demand in the respiratory and cough care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on chest care and pulmonary health portfolios.

Why should medical distributors include Cufsniff 30 Tablet in their product range?

Medical distributors and agencies can benefit from the consistent demand for mucolytic therapies used in productive cough, bronchitis, respiratory tract congestion, and mucus-related breathing discomfort. Cufsniff 30 Tablet helps strengthen a comprehensive respiratory care product portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for Cufsniff 30 Tablet?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Cufsniff 30 Tablet with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for Cufsniff 30 Tablet distribution?

Wholesalers and medical agencies benefit from strong seasonal prescription demand, fast-moving respiratory care sales, reliable supply chain support, and good margins when partnering for Cufsniff 30 Tablet distribution.

How can I become a distributor or franchise partner for Cufsniff 30 Tablet?

Medical distributors, stockists, and wholesalers interested in Cufsniff 30 Tablet can contact Cafoli LifeCare Pvt Ltd to discuss franchise opportunities, bulk supply requirements, pricing, and distribution support.